SecBot SecBot
SECBOTREPLAY Home › Report › HRMY

HRMY · Harmony Biosciences announced the departure of CFO Sandip Kapadia and…

Harmony Biosciences Holdings, Inc. · 8-K filed Apr 14, 2026 at 08:15 ET

At the news

MIXEDIMPACT 6/10

8-K filed Apr 14, 2026 at 08:15 ET

Harmony Biosciences announced the departure of CFO Sandip Kapadia and the immediate appointment of Glenn Reicin as his replacement. The company reiterated its 2026 net revenue guidance of $1.0–1.04 billion. This leadership transition follows a recent proxy fight, suggesting ongoing board-level tensions.

  • CFO Sandip Kapadia stepped down effective April 14, 2026, after serving since 2021
  • Glenn Reicin appointed as new CFO effective immediately, with a $500,000 base salary and $3 million option grant
  • Kapadia's separation agreement includes $539,000 severance and accelerated vesting of October 2023 equity awards
  • Company reaffirmed 2026 net revenue guidance of $1.0–1.04 billion

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access